Current status of syngeneic marrow transplantation and its relevance to autografting.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D006087:Graft vs Host Reaction; D006801:Humans; D007938:Leukemia / Q000628:therapy; D007945:Leukemia, Lymphoid / Q000628:therapy; D007951:Leukemia, Myeloid / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D014182:Transplantation, Autologous; D014185:Transplantation, Isogeneic
D000970:Antineoplastic Agents; D003520:Cyclophosphamide